BriaCell Therapeutics (BCTX) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free BCTX Stock Alerts $1.50 +0.12 (+8.70%) (As of 08:46 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:00 AM | globenewswire.comBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct OfferingApril 24, 2024 | globenewswire.comBriaCell Announces Oral and Poster Presentations at ASCO 2024April 10, 2024 | globenewswire.comBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApril 9, 2024 | finance.yahoo.comBriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACRMarch 20, 2024 | sg.finance.yahoo.comBriaCell Therapeutics Corp. (BCTX)March 7, 2024 | globenewswire.comBriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ImmunotherapiesMarch 6, 2024 | globenewswire.comBriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR ConferenceFebruary 27, 2024 | finance.yahoo.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 27, 2024 | globenewswire.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 14, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. (BCTX) stock forecast and price targetFebruary 7, 2024 | marketbeat.comBriaCell Therapeutics (NASDAQ:BCTX) Trading 5.3% Higher BriaCell Therapeutics (NASDAQ:BCTX) Trading Up 5.3%January 30, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingDecember 28, 2023 | finance.yahoo.comBriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDecember 27, 2023 | benzinga.comBriaCell Therapeutics Stock (NASDAQ:BCTX) Dividends: History, Yield and DatesDecember 20, 2023 | msn.comBriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated PatientsDecember 20, 2023 | finance.yahoo.comBriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient SubsetDecember 6, 2023 | finance.yahoo.comBriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSNovember 8, 2023 | finance.yahoo.comBCTX: November 2023 SITC PosterNovember 4, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - New BCTXNovember 1, 2023 | finance.yahoo.comBCTX: Year in ReviewOctober 24, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - NewOctober 11, 2023 | finance.yahoo.comBriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo ClinicAugust 31, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersAugust 31, 2023 | finance.yahoo.comBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerAugust 28, 2023 | bizjournals.comBriaCell receives court approval to launch spinoff aimed at accelerating cancer drug developmentJuly 10, 2023 | finance.yahoo.comBCTX: Pivotal Study Protocol ClearedJuly 9, 2023 | marketbeat.comK.J. Harrison & Partners Inc Lowers Position in BriaCell Therapeutics Corp. (NASDAQ:BCTX)K.J. Harrison & Partners Inc reduced its stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX - Free Report) by 75.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 105,933 shares of the company's stock after selliJune 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price TargetJune 27, 2023 | baystreet.caFive Top Companies Fighting for the Treatment of Metastatic Breast CancerJune 27, 2023 | finance.yahoo.comFDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerMay 25, 2023 | baystreet.caThere are Positive Developments in the Treatment of Metastatic Breast CancerMay 15, 2023 | baystreet.caFive Impressive Metastatic Cancer Treatment Stocks to Own TodayMay 15, 2023 | finance.yahoo.comBriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.May 1, 2023 | marketbeat.comFY2023 EPS Estimates for BriaCell Therapeutics Corp. (NASDAQ:BCTX) Lowered by AnalystBriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Rating) - Zacks Small Cap reduced their FY2023 earnings per share (EPS) estimates for shares of BriaCell Therapeutics in a research note issued on Thursday, April 27th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earApril 27, 2023 | finance.yahoo.comBCTX: Posters Galore at AACRApril 10, 2023 | finance.yahoo.comBriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth PlansApril 3, 2023 | marketbeat.comShort Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 6.3%BriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Rating) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,500,000 shares, a decrease of 6.3% from the February 28th total of 1,600,000 shares. Based on an average daily volume of 211,500 shares, the days-to-cover ratio is currently 7.1 days. Currently, 14.6% of the shares of the stock are short sold.March 30, 2023 | seekingalpha.comBriaCell plans spin-out of some pre-clinical assets into new entityMarch 24, 2023 | finanznachrichten.deUSA News Group: Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast CancerMarch 14, 2023 | finance.yahoo.comA BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last yearMarch 9, 2023 | finance.yahoo.comBCTX: 82% Survival BenefitFebruary 28, 2023 | seekingalpha.comBCTX BriaCell Therapeutics Corp.February 24, 2023 | marketbeat.comBriaCell Therapeutics (NASDAQ:BCTX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of BriaCell Therapeutics in a report on Friday.February 7, 2023 | marketbeat.comBriaCell Therapeutics Corp. (NASDAQ:BCTX) Shares Bought by Virtu Financial LLCVirtu Financial LLC lifted its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Rating) by 362.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 48,347 shares of the company's stock after purchasing an additional 37,894 shares during tJanuary 23, 2023 | marketbeat.comBriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 5.7% in DecemberBriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Rating) was the target of a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 1,320,000 shares, a drop of 5.7% from the December 15th total of 1,400,000 shares. Approximately 12.7% of the company's shares are sold short. Based on an average trading volume of 236,800 shares, the days-to-cover ratio is presently 5.6 days.January 20, 2023 | finance.yahoo.comLab Notes: Amicus founder gets national honor; Capstan and Code Bio land on list of companies to watchDecember 19, 2022 | finance.yahoo.comBCTX: Down in San AntoneDecember 1, 2022 | benzinga.comBriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer PatientsNovember 10, 2022 | finance.yahoo.comBriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual MeetingOctober 31, 2022 | finance.yahoo.comBCTX: Fiscal Year 2022 Results Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Alert: Is the U.S. Implementing a Digital Dollar? (Ad)Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource in navigating this uncertain terrain. Inside, you'll find expert insights, strategies, and actionable steps to shield your wealth from the impending digital dollar storm. Limited time offer! Claim your guide today and stay ahead of the digital dollar revolution. BCTX Media Mentions By Week BCTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCTX News Sentiment▼1.250.54▲Average Medical News Sentiment BCTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCTX Articles This Week▼20▲BCTX Articles Average Week Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI News FBIO News MRKR News APLM News PMN News IPA News SPRB News JAN News DRRX News VIRX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCTX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate CapitalHow Biden has already won 2024Porter & Company348 million Americans lives to END as we know it?The Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
